Literature DB >> 16479508

Recovery of drug-resistant influenza virus from immunocompromised patients: a case series.

Michael G Ison1, Larisa V Gubareva, Robert L Atmar, John Treanor, Frederick G Hayden.   

Abstract

Influenza virus with resistance to antiviral drugs emerges with increased frequency in immunocompromised patients and can limit the benefit of M2 and neuraminidase (NA) inhibitors. We document 3 cases of influenza in severely immunocompromised patients from whom virus variants with molecular markers of resistance to anti-influenza drugs were recovered. Virus variants recovered from 2 patients had mutations in the M2, NA (with a previously recognized Glu119Val NA substitution), and hemagglutinin genes. We describe a novel Asp198Asn NA mutation in an influenza B virus and its decreased susceptibility to both oseltamivir and zanamivir.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479508     DOI: 10.1086/500465

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  95 in total

1.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase.

Authors:  Ye Wang; Di Wu; Dahai Yu; Zhiyong Wang; Li Tian; Yanyan Wang; Weiwei Han; Xuexun Fang
Journal:  J Mol Model       Date:  2012-01-27       Impact factor: 1.810

3.  Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.

Authors:  Elodie Ghedin; Jennifer Laplante; Jay DePasse; David E Wentworth; Roberto P Santos; Martha L Lepow; Joanne Porter; Kathleen Stellrecht; Xudong Lin; Darwin Operario; Sara Griesemer; Adam Fitch; Rebecca A Halpin; Timothy B Stockwell; David J Spiro; Edward C Holmes; Kirsten St George
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

Review 4.  Influenza susceptibility, severity, and shedding in HIV-infected adults: a review of the literature.

Authors:  Anandi N Sheth; Keri N Althoff; John T Brooks
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 5.  Influenza.

Authors:  John H Beigel
Journal:  Crit Care Med       Date:  2008-09       Impact factor: 7.598

6.  Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase.

Authors:  Jennifer L McKimm-Breschkin; Janelle Williams; Susan Barrett; Kim Jachno; Mandy McDonald; Peter G Mohr; Takehiko Saito; Masato Tashiro
Journal:  J Antimicrob Chemother       Date:  2013-06-11       Impact factor: 5.790

7.  In Vitro and In Vivo Characterization of Novel Neuraminidase Substitutions in Influenza A(H1N1)pdm09 Virus Identified Using Laninamivir-Mediated In Vitro Selection.

Authors:  Khristine Kaith S Lloren; Jin Jung Kwon; Won-Suk Choi; Ju Hwan Jeong; Su Jeong Ahn; Young Ki Choi; Yun Hee Baek; Min-Suk Song
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

8.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

Review 9.  2009 H1N1 influenza.

Authors:  Seth J Sullivan; Robert M Jacobson; Walter R Dowdle; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2009-12-10       Impact factor: 7.616

10.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.